Cargando…
Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2005
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1297624/ https://www.ncbi.nlm.nih.gov/pubmed/16277704 http://dx.doi.org/10.1186/cc3798 |
| _version_ | 1782126234197557248 |
|---|---|
| author | Rondon, Eliseo Venkataraman, Ramesh |
| author_facet | Rondon, Eliseo Venkataraman, Ramesh |
| author_sort | Rondon, Eliseo |
| collection | PubMed |
| description | |
| format | Text |
| id | pubmed-1297624 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2005 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-12976242005-12-01 Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels Rondon, Eliseo Venkataraman, Ramesh Crit Care Journal Club Critique BioMed Central 2005 2005-08-05 /pmc/articles/PMC1297624/ /pubmed/16277704 http://dx.doi.org/10.1186/cc3798 Text en Copyright © 2005 BioMed Central Ltd |
| spellingShingle | Journal Club Critique Rondon, Eliseo Venkataraman, Ramesh Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels |
| title | Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels |
| title_full | Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels |
| title_fullStr | Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels |
| title_full_unstemmed | Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels |
| title_short | Afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels |
| title_sort | afelimomab led to a modest mortality benefit in patients with severe sepsis and elevated interleukin-6 levels |
| topic | Journal Club Critique |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1297624/ https://www.ncbi.nlm.nih.gov/pubmed/16277704 http://dx.doi.org/10.1186/cc3798 |
| work_keys_str_mv | AT rondoneliseo afelimomabledtoamodestmortalitybenefitinpatientswithseveresepsisandelevatedinterleukin6levels AT venkataramanramesh afelimomabledtoamodestmortalitybenefitinpatientswithseveresepsisandelevatedinterleukin6levels |